PCM
GNMK

Portolan Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Portolan Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-164,717
Closed -$2.4M – 192
2020
Q4 		$2.4M Sell
164,717
-54,207
-25% -$718K 0.22% 122
2020
Q3 		$3.11M Sell
218,924
-772,573
-78% -$11.8M 0.35% 92
2020
Q2 		$14.6M Buy
991,497
+98,407
+11% +$1,000K 1.67% 12
2020
Q1 		$3.68M Buy
+893,090
New +$4.19M 0.55% 62

Other funds holding GNMK

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Portolan Capital Management's GNMK Position: Q1 2021 in Review

Portolan Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2021, closing a stake of 164,717 shares — an estimated $2.4M sold.

Portolan Capital Management first reported a position in GNMK in Q1 2020 and held it in 4 quarters. The position peaked at $14.6M in Q2 2020. 164 funds tracked by Wall St. Rank hold GNMK as of Q1 2021.

  • Portolan Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q1 2021 after selling out during the quarter.
  • Portolan Capital Management sold 164,717 GenMark Diagnostics, Inc shares in Q1 2021, an estimated $2.4M.
  • Portolan Capital Management first reported a position in GenMark Diagnostics, Inc in Q1 2020 and held it in 4 quarters.
  • Portolan Capital Management's GenMark Diagnostics, Inc position peaked at $14.6M in Q2 2020.
  • 164 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2021.

Based on Portolan Capital Management's 13F filing for Q1 2021, filed 17 May 2021.